Skip to content
Prosidion

Prosidion Ltd.

Biochemical Cell Research and Diabetes

Menu
  • Home
  • protein
  • DNA
  • LDHB Rabbit Polyclonal Antibody
  • Distributors
  • Contact Us
Menu
Discovering common pathogenetic processes between COVID-19 and diabetes mellitus by differential gene expression pattern analysis

Discovering common pathogenetic processes between COVID-19 and diabetes mellitus by differential gene expression pattern analysis

Posted on September 12, 2021July 24, 2021 by Andres
Coronavirus illness 2019 (COVID-19) is an infectious illness precipitated by the newly found coronavirus, SARS-CoV-2. Increased severity of COVID-19 has been noticed in sufferers with diabetes mellitus (DM). This research aimed to determine common transcriptional signatures, regulators and pathways between COVID-19 and DM. We have built-in human whole-genome transcriptomic datasets from COVID-19 and DM, adopted by practical evaluation with gene ontology (GO) and pathway analyses.
In peripheral blood mononuclear cells (PBMCs), among the many upregulated differentially expressed genes (DEGs), 32 had been discovered to be generally modulated in COVID-19 and sort 2 diabetes (T2D), whereas 10 DEGs had been generally downregulated. As regards sort 1 diabetes (T1D), 21 DEGs had been generally upregulated, and 29 DEGs had been generally downregulated in COVID-19 and T1D. Moreover, 35 DEGs had been generally upregulated in SARS-CoV-2 contaminated pancreas organoids and T2D islets, whereas 14 had been generally downregulated.
Several GO phrases had been present in common between COVID-19 and DM. Prediction of the putative transcription components concerned within the upregulation of genes in COVID-19 and DM recognized RELA to be implicated in each PBMCs and pancreas. Here, for the primary time, we have now characterised the organic processes and pathways generally dysregulated in COVID-19 and DM, which might be within the subsequent future used for the design of customized remedy of COVID-19 sufferers affected by DM as comorbidity.

Cisplatin’s potential for sort 2 diabetes repositioning by inhibiting CDKN1A, FAS, and SESN1

Cisplatin is a DNA-damaging chemotherapeutic agent used for treating most cancers. Based on cDNA dataset analysis, we investigated how cisplatin modified gene expression and noticed cisplatin-induced dysregulation and system-level variations referring to insulin resistance and sort 2 diabetes mellitus (T2DM). T2DM is a multifactorial illness affecting 462 million individuals on the planet, and drug-induced T2DM is a severe problem.
To perceive this etiology, we designed an integrative, system-level research to determine associations between cisplatin-induced differentially expressed genes (DEGs) and T2DM. From an inventory of differential expressed genes, cisplatin downregulated the cyclin-dependent kinase inhibitor 1 (CDKN1A), tumor necrosis issue (FAS), and sestrin-1 (SESN1) genes chargeable for modifying signaling pathways, together with the p53, JAK-STAT, FOXO, MAPK, mTOR, P13-AKT, Toll-like receptor (TLR), adipocytokine, and insulin signaling pathways. These enriched pathways had been expressively related to the illness.
We noticed important gene signatures, together with SMAD3, IRS, PDK1, PRKAA1, AKT, SOS, RAS, GRB2, MEK1/2, and ERK, interacting with supply genes. This research revealed the worth of system genetics for figuring out the cisplatin-induced genetic variants chargeable for the development of T2DM. Also, by cross-validating gene expression information for T2DM islets, we discovered that downregulating IRS and PRK households is important in insulin and T2DM signaling pathways.
Cisplatin, by inhibiting CDKN1A, FAS, and SESN1, promotes IRS and PRK exercise in the same technique to rosiglitazone (a preferred drug used for T2DM remedy). Our integrative, network-based strategy might help in understanding the drug-induced pathophysiological mechanisms of diabetes.

Relationship between cardiovascular and kidney disease in a sample of patients with diabetes in today’s world

Kidney disease is one of the microvascular complications of diabetes mellitus (DM) with little research and a great relationship with cardiovascular disease (CVD). The objective of this work is to characterize the prevalence of kidney disease in a population of patients with type 2 diabetes who attend outpatient management by cardiology, determine its degree of investigation and its possible effect on the achievement of therapeutic objectives and the use of antidiabetics with cardiorenal protective effect.
Discovering common pathogenetic processes between COVID-19 and diabetes mellitus by differential gene expression pattern analysis
Methods: Cross-sectional, observational and multicenter study carried out in 44 centers in Argentina between May and July 2019. Results: 693 patients were included with an established CVD prevalence of 47.5% (329 patients) and 42.3% of microvascular disease . Albuminuria was only assessed in 46.2% of the patients and it was significantly higher in the group with IR. CVD in patients with IR was higher than in those without IR (64.8% vs. 42.2%; p = 0.0001). The presence of albuminuria was accompanied by a higher prevalence of CVD.
The scope of the therapeutic targets was limited and no differences were recognized as a function of RI, with the exception of the LDL target. Low prescription of antidiabetic drugs with proven cardiorenal benefit was observed. Conclusions: The work highlights the importance of the active search for kidney disease in patients with diabetes, which reveals the low scope of therapeutic goals and the prescription of antidiabetic drugs with cardiorenal benefit.

Evaluation of affiliation research and a scientific evaluation and meta-analysis of VDR polymorphisms in sort 2 diabetes mellitus threat

Numerous unique research and four revealed meta-analyses have reported the affiliation between the Vitamin D receptor (VDR) BsmI, FokI, ApaI, and TaqI polymorphisms and sort 2 diabetes mellitus (T2DM) threat. However, the outcomes had been inconsistent.
Therefore, an up to date meta-analysis was carried out to additional discover these points.To additional discover the affiliation between the VDR BsmI, FokI, ApaI, and TaqI polymorphisms and T2DM threat.PubMed, EMBASE, Scopus, and Wanfang databases had been searched. The following search technique had been used: (VDR OR vitamin D receptor) AND (polymorphism OR variant OR mutation) AND (diabetes OR mellitus OR diabetes mellitus).
Pooled crude odds ratios with 95% confidence intervals had been utilized to guage the energy of affiliation in 5 genetic fashions. Statistical heterogeneity, the take a look at of publication bias, and sensitivity analysis had been carried out utilizing the STATA software program (Version 12.0). To consider the credibility of statistically important associations, we utilized the false-positive report chances (FPRP) and Bayesian false discovery chance (BFDP) take a look at.
Overall, the VDR BsmI polymorphism was related to a considerably decreased T2DM threat in Asians; the VDR FokI polymorphism was related to a considerably decreased T2DM threat in Asians, African international locations, and Asian international locations; the VDR ApaI polymorphism was related to a considerably decreased T2DM threat in Caucasians and North American international locations.On the VDR ApaI polymorphism, a considerably elevated T2DM threat was present in a blended inhabitants.

HeLa Cell Extract

30R-AG012 Fitzgerald 100 ug 418.8 EUR
Description: Glutathiolated human epithelial carcinoma cell (HeLa) extract

HeLa Cell Slide

17-001 ProSci 1 pack 216.6 EUR
Description: HeLa S3 (cervix; adenocarcinoma)

cDNA from Human Tumor Cell Line: Hela

C1255811 Biochain 40 reactions 451.2 EUR
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes.

Inducible GFP Hela stable cell line

SC036 GenTarget 2 x 106 cell/ml x 1ml 1800 EUR
Description: InducibleGFP expression stable cell line in Hela cells, with Neomycin and puromycin resitance

Inducible RFP Hela stable cell line

SC037 GenTarget 2 x 106 cell/ml x 1ml 1800 EUR
Description: Inducible RFP expression stable cell line in Hela with Blasticidin and Puromycin resistance

Hela / Cas9 (Bad) Stable Cell Line

SC045-Cas9-Bsd GenTarget 2 x 106 cell/ml x 1ml 1269.6 EUR
Description: Cas9 expression stable cell line with Blasticidin resistance in Hela human cervical cancer cells.

Gene Knock-Out HR Targeting Vector [MCS1-EF1?-RFP-T2A-Puro-pA-MCS2]

HR110PA-1 SBI 10 ug 1227.6 EUR

Gene Knock-Out HR Targeting Vector [MCS1-EF1a-GFP-T2A-Puro-pA-MCS2]

HR410PA-1 SBI 10 ug 1227.6 EUR

Gene Knock-Out HR Targeting Vector [MCS1-EF1a-RFP-T2A-Hygro-pA-MCS2]

HR510PA-1 SBI 10 ug 1227.6 EUR

Human Hela Whole Cell Lysate

LYSATE0023 BosterBio 200ug 180 EUR
Description: This cell lysate is prepared from human hela using Boster's RIPA Lysis Buffer (AR0105) using a standard whole cell lysate protocol. The concentration was determined using the BCA assay process and then diluted using Dithiothreitol (DTT) and a reducing SDS sample loading buffer, heated for 5 minutes at 100˚C.

TARGATT? Knock-in iPSC Generation (Master Cell Line)

AST-1100 Applied StemCell 1 vial of 1X10^6 cells Ask for price
Description: 6 month

H2O2 stimulated HeLa Cell Lysate (Human epithelial cell line)

LF-R0002 Abfrontier Each 100 ul 145.2 EUR
Description: HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate - H2O2 stimulated

Genomic DNA from Human Tumor Cell Line: Hela

D1255811 Biochain 100 ug 291.6 EUR
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes.

Total Protein from Human Tumor Cell Line: Hela

P1255811 Biochain 1 mg 256.8 EUR
Description: Can be used for various proteomics studies in both normal and pathological cases. It is an excellent control and suitable for educational purposes. This product is prepared from whole tissue homogenates and has undergone SDS-PAGE quality control analysis. The protein is stored in a buffer with protease inhibitor cocktail fo prevent degradation.

Membrane Protein from Human Tumor Cell Line: Hela

P3255811 Biochain 0.1 mg 342 EUR
Description: Can be used for various proteomics studies in both normal and pathological cases. It is an excellent control and suitable for educational purposes. This product is prepared from whole tissue homogenates and has undergone SDS-PAGE quality control analysis. The protein is stored in a buffer with protease inhibitor cocktail fo prevent degradation.

Total RNA from Human Tumor Cell Line: Hela

R1255811-50 Biochain 50 ug 232.8 EUR
Description: Can be used for various studies in the realm of gene expression and regulation, both normal and pathological. It is an excellent control and suitable for educational purposes.

TARGATT? Knock-in Mouse Cell Line Generation Kit (Master Cell Line)

AST-7001 Applied StemCell 1 Kit Ask for price
Description: 6 month

Rrad/ Rat Rrad ELISA Kit

ELI-14921r Lifescience Market 96 Tests 1063.2 EUR

HeLa Cell Lysate (Whole Cell)

LYSATE0001 Cusabio 200ug 180 EUR
Description: This whole cell lysate is prepared from Hela cells using Boster's RIPA Lysis Buffer (AR0105) using a standard whole cell lysate protocol. The concentration was determined using the BCA assay process and then diluted using Dithiothreitol (DTT) and a reducing SDS sample loading buffer, heated for 5 minutes at 100˚C.

Human ; HeLa (#1)

02-723 Sceti 100ng 481.2 EUR
Description: The Human ; HeLa (#1) is available in Europe and for worldwide shipping via Gentaur.

Rrad 3'UTR GFP Stable Cell Line

TU269725 ABM 1.0 ml Ask for price

RRAD 3'UTR Luciferase Stable Cell Line

TU022380 ABM 1.0 ml 1672.8 EUR

Rrad 3'UTR Luciferase Stable Cell Line

TU219725 ABM 1.0 ml Ask for price

RRAD 3'UTR GFP Stable Cell Line

TU072380 ABM 1.0 ml 1672.8 EUR

Rrad 3'UTR GFP Stable Cell Line

TU168183 ABM 1.0 ml Ask for price

Rrad 3'UTR Luciferase Stable Cell Line

TU118183 ABM 1.0 ml Ask for price

TARGATT? Knock-in CHO Generation Kit (Master Cell Line)

AST-1200 Applied StemCell 1 Kit Ask for price
Description: 12 month

TARGATT? Knock-in HEK293 Generation Kit (Master Cell Line)

AST-1300 Applied StemCell 1 Kit Ask for price
Description: 12 month

RRAD Peptide

43-008P ProSci 0.1 mg 405.6 EUR
Description: RRAD Peptide

RRAD antibody

70R-50359 Fitzgerald 100 ul 292.8 EUR
Description: Purified Polyclonal RRAD antibody

RRAD antibody

70R-5797 Fitzgerald 50 ug 560.4 EUR
Description: Rabbit polyclonal RRAD antibody raised against the middle region of RRAD

RRAD antibody

70R-5798 Fitzgerald 50 ug 560.4 EUR
Description: Rabbit polyclonal RRAD antibody raised against the middle region of RRAD

RRAD Antibody

37229-100ul SAB 100ul 302.4 EUR

RRAD Antibody

1-CSB-PA779820 Cusabio
  • 380.40 EUR
  • 292.80 EUR
  • 100ul
  • 50ul
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:50-1:200

RRAD siRNA

20-abx932133 Abbexa
  • 661.20 EUR
  • 878.40 EUR
  • 15 nmol
  • 30 nmol

RRAD Antibody

CSB-PA233809-100ul Cusabio 100ul 379.2 EUR
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF;WB:1:500-1:3000, IHC:1:50-1:100, IF:1:100-1:500

RRAD Antibody

1-CSB-PA248209 Cusabio
  • 380.40 EUR
  • 292.80 EUR
  • 100ul
  • 50ul
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:5000, IHC:1:25-1:100

RRAD Antibody

1-CSB-PA003910 Cusabio
  • 266.40 EUR
  • 234.00 EUR
  • 100ug
  • 50ug
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human. This antibody is Unconjugated. Tested in the following application: WB, IHC, IF, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.IF:1/200-1/1000.ELISA:1/20000

RRAD Antibody

R34275-100UG NSJ Bioreagents 100 ug 399 EUR

RRAD Antibody

CSB-PA233809- Cusabio each 402 EUR
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF;WB:1:500-1:3000, IHC:1:50-1:100, IF:1:100-1:500

HeLa cells

C0008001 Addexbio One Frozen vial 546 EUR

RRAD sgRNA CRISPR Lentivector set (Human)

K2069901 ABM 3 x 1.0 ug 406.8 EUR

Cas9-Expressing HeLa Cell Pool

78161 BPS Bioscience 2 vials 795 EUR
Description: Cas9 (Streptococcus pyogenes CRISPR associated protein 9) is an endonuclease enzyme that, when recruited to a specific DNA sequence by the sgRNA (single guide RNA), introduces a double stranded break into the DNA. This double stranded break is repaired in mammalian cells either through Non-Homologous End Joining or Homologous Recombination. Non-Homologous End Joining often results in the deletion or insertion of several base pairs at the cut site, which, when resulting in a frameshift, causes the functional inactivation of the targeted gene. Cas9-expressing HeLa cells can be transduced or electroporated with sgRNA targeting a gene of interest to quickly generate knock-out cell pools or cell lines.

Basic HR Targeting Vector [MCS1-LoxP-MCS2-MCS3-pA-LoxP-MCS4] for Gene Knock-In/Out

HR100PA-1 SBI 10 ug 1125.6 EUR

Human RRAD shRNA Plasmid

20-abx954199 Abbexa
  • 961.20 EUR
  • 1345.20 EUR
  • 150 µg
  • 300 µg

RRAD ELISA KIT|Human

EF005507 Lifescience Market 96 Tests 826.8 EUR

RRAD Recombinant Protein (Human)

RP095493 ABM 100 ug Ask for price

Human HeLa Whole Cell Lysate, TNFa Stimulated

HCL-2000 Alpha Diagnostics 100ug 255.6 EUR

Human HeLa (Cervix Adenocarcinoma) Cell Nuclear Extract

HCL-2008 Alpha Diagnostics 100ug 270 EUR

Human HeLa (Cervix Adenocarcinoma) Whole Cell Lysate

HCL-2009 Alpha Diagnostics 1 mg 628.8 EUR

RRAD sgRNA CRISPR Lentivector (Human) (Target 1)

K2069902 ABM 1.0 ug DNA 184.8 EUR

RRAD sgRNA CRISPR Lentivector (Human) (Target 2)

K2069903 ABM 1.0 ug DNA 184.8 EUR

RRAD sgRNA CRISPR Lentivector (Human) (Target 3)

K2069904 ABM 1.0 ug DNA 184.8 EUR

RRAD Blocking Peptide

33R-10070 Fitzgerald 100 ug 216 EUR
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of RRAD antibody, catalog no. 70R-5798

RRAD Blocking Peptide

33R-4793 Fitzgerald 100 ug 216 EUR
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of RRAD antibody, catalog no. 70R-5797

RRAD Blocking Peptide

20-abx063234 Abbexa
  • 326.40 EUR
  • 493.20 EUR
  • 1 mg
  • 5 mg

Polyclonal RRAD Antibody

APR05556G Leading Biology 0.1ml 580.8 EUR
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human RRAD . This antibody is tested and proven to work in the following applications:

RRAD Conjugated Antibody

C37229 SAB 100ul 476.4 EUR

Chang Liver (HeLa)

C0050007 Addexbio One Frozen vial 651.6 EUR

HeLa Antigen Concentrate

F813X Cygnus Technologies 1 ml 632.4 EUR
Description: HeLa Antigen Concentrate by Cygnus Technologies is available in Europe via Gentaur.

HeLa Membrane Lysate

XBL-10439 ProSci 0.1 mg 619.8 EUR
Description: Hela (Human cervix Adenocarcinoma) cell membrane protein lysate was prepared by isolating the membrane protein from whole tissue homogenates using a proprietary technique. The Hela (Human cervix Adenocarcinoma) cell was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The membrane protein is provided in a buffer including HEPES (pH 7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the isolated Hela (cervix Adenocarcinoma) cell membrane protein pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The isolated Hela (cervix Adenocarcinoma) cell membrane protein is then Western analyzed by either GAPDH or β-actin antibody to confirm there is no signal or very weak signal.

Hela Nuclear Extract

X12001 EpiGentek 1000 µg Ask for price

HeLa Nuclear Extract

1641-01 Biovision each 222 EUR

HeLa Nuclear Extract

1641-1 Biovision each 405.6 EUR

RRAD ORF Vector (Human) (pORF)

ORF031832 ABM 1.0 ug DNA 486 EUR

Gene Knock-Out HR Targeting Vector w/Single Selection Marker (Blasticidin) and Negative Selection (TK) Against Random Integration

HR720PA-1 SBI 10 µg 1374 EUR

293AAV Cell Line

AAV-100 Cell Biolabs 1 vial 609.6 EUR
Description: The 293AAV Cell Line is derived from the parental 293 cells but selected for attributes that increase AAV production, including firmer attachment and larger surface area.

293AD Cell Line

AD-100 Cell Biolabs 1 vial 553.2 EUR
Description: The 293AD Cell Line is derived from the parental 293 cells but selected for attributes that increase adenovirus production, including firmer attachment and larger surface area.

293LTV Cell Line

LTV-100 Cell Biolabs 1 vial 609.6 EUR
Description: The 293LTV Cell Line is derived from the parental 293 cells but selected for attributes that increase lentiviral production, including fimrer attachment and larger surface area.

293RTV Cell Line

RV-100 Cell Biolabs 1 vial 609.6 EUR
Description: The 293RTV Cell Line is derived from the parental 293 cells but selected for attributes that increase retroviral production, including fimrer attachment and larger surface area.

Rrad sgRNA CRISPR Lentivector set (Rat)

K7052701 ABM 3 x 1.0 ug 406.8 EUR

Rrad sgRNA CRISPR Lentivector set (Mouse)

K3480701 ABM 3 x 1.0 ug 406.8 EUR

GAS Reporter (Luc) - HeLa Cell Line (IFNγ/JAK/STAT1 Pathway)

79041 BPS Bioscience 2 vials 1810 EUR
Description: The GAS reporter (Luc)-HeLa cell line is designed to monitor the activity of interferon gamma-induced signal transduction pathways in cultured cells by measuring activated STAT1 homodimers. It contains a firefly luciferase gene driven by three copies of the interferon gamma-activated sites (GAS) located upstream of the minimal TATA promoter. IFNγ first binds to a heterodimeric receptor consisting of two chains, IFNGR1 and IFNGR2, causing its dimerization and the activation of specific Janus family kinases (JAK1 and JAK2). Two STAT1 molecules associate with this ligand-activated receptor complex and are activated by phosphorylation to form active homodimer. The active STAT1 homodimers translocate to the nucleus where they bind interferon gamma-activated sites (GAS) in the promoter of IFNγ inducible genes, including luciferase reporter gene.

Gene Knock-Out HR Targeting Vector w/Dual Selection Markers (GFP+Puro) and Negative Selection (TK) Against Random Integration

HR700PA-1 SBI 10 µg 1374 EUR

Gene Knock-Out HR Targeting Vector w/Dual Selection Markers (RFP+Hygro) and Negative Selection (TK) Against Random Integration

HR710PA-1 SBI 10 µg 1374 EUR

293/GFP Cell Line

AKR-200 Cell Biolabs 1 vial 686.4 EUR
Description: 293/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line.

T47D/GFP Cell Line

AKR-208 Cell Biolabs 1 vial 686.4 EUR
Description: T47D/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line.

A549/GFP Cell Line

AKR-209 Cell Biolabs 1 vial 686.4 EUR
Description: A549/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line.

NIH3T3/GFP Cell Line

AKR-214 Cell Biolabs 1 vial 686.4 EUR
Description: NIH3T3/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line.

NIH3T3/Cas9 Cell Line

AKR-5104 Cell Biolabs 1 vial 686.4 EUR

293/Cas9 Cell Line

AKR-5110 Cell Biolabs 1 vial 686.4 EUR

TARGATT? Knock-in iPSC Genotyping Kit

AST-1102 Applied StemCell 1 Kit Ask for price
Description: 12 month

Human HeLa (Cervix Adenocarcinoma) Cell Nuclear Extract - Doxorubicin Stimulated

HCL-2004 Alpha Diagnostics 100ug 270 EUR

Human HeLa (Cervix Adenocarcinoma) Cell Nuclear Extract - Etoposide Stimulated

HCL-2005 Alpha Diagnostics 100ug 270 EUR

Human HeLa (Cervix Adenocarcinoma) Cell Nuclear Extract - Nocodozole Stimulated

HCL-2006 Alpha Diagnostics 100ug 270 EUR

Human HeLa (Cervix Adenocarcinoma) Cell Nuclear Extract - TNFa Stimulated

HCL-2007 Alpha Diagnostics 100ug 270 EUR

Human HeLa (Cervix Adenocarcinoma) Whole Cell Lysate - Doxorubicin Stimulated

HCL-2010 Alpha Diagnostics 100ug 255.6 EUR

Human HeLa (Cervix Adenocarcinoma) Whole Cell Lysate - Etoposide Stimulated

HCL-2011 Alpha Diagnostics 100ug 255.6 EUR

RRAD Recombinant Protein (Rat)

RP226925 ABM 100 ug Ask for price

RRAD Recombinant Protein (Mouse)

RP169340 ABM 100 ug Ask for price

HeLa HCP ELISA Kit

F810 Cygnus Technologies 1 kit (96 wells plate) 1296 EUR
Description: HeLa HCP ELISA Kit by Cygnus Technologies is available in Europe via Gentaur.

Anti-HeLa: HRP Conjugate

F811 Cygnus Technologies 12 ml 678 EUR
Description: Anti-HeLa: HRP Conjugate by Cygnus Technologies is available in Europe via Gentaur.

Hela-RFP stable cells

SC031-Puro GenTarget 2 x 106 cell/ml x 1ml 930 EUR
Description: RFP expression stable cell line in Hela cells with Puromycin marker.

Native Nucleosome (HeLa-derived)

52039 BPS Bioscience 0.6 mg 695 EUR
Description: Native nucleosome purified from human HeLa cells.

Microplate Swing-Out Centrifuge

abx725026-1Unit Abbexa 1 Unit 1771.2 EUR

Clinical Swing-Out Centrifuge

abx725027-1Unit Abbexa 1 Unit 1771.2 EUR

Gene Knock-Out HR Targeting Vector with TK selection [MCS1-LoxP-EF1?-GFP-T2A-Puro-P2A-hsvTK-pA-LoxP-MCS2]

HR210PA-1 SBI 10 ug 1374 EUR

Rrad sgRNA CRISPR Lentivector (Rat) (Target 1)

K7052702 ABM 1.0 ug DNA 184.8 EUR

Rrad sgRNA CRISPR Lentivector (Rat) (Target 2)

K7052703 ABM 1.0 ug DNA 184.8 EUR

Rrad sgRNA CRISPR Lentivector (Rat) (Target 3)

K7052704 ABM 1.0 ug DNA 184.8 EUR

Rrad sgRNA CRISPR Lentivector (Mouse) (Target 1)

K3480702 ABM 1.0 ug DNA 184.8 EUR

Rrad sgRNA CRISPR Lentivector (Mouse) (Target 2)

K3480703 ABM 1.0 ug DNA 184.8 EUR

Rrad sgRNA CRISPR Lentivector (Mouse) (Target 3)

K3480704 ABM 1.0 ug DNA 184.8 EUR

SKOV-3/Luc Cell Line

AKR-232 Cell Biolabs 1 vial 686.4 EUR
Description: SKOV-3/Luc Cell Line stably expresses luciferase and otherwise exhibits the same characteristics of the parental cell line.

MCF-7/Luc Cell Line

AKR-234 Cell Biolabs 1 vial 686.4 EUR
Description: MCF-7/Luc Cell Line stably expresses luciferase and otherwise exhibits the same characteristics of the parental cell line.

OVCAR-5/RFP Cell Line

AKR-254 Cell Biolabs 1 vial 686.4 EUR
Description: OVCAR-5/RFP Cell Line stably expresses RFP and otherwise exhibits the same characteristics of the parental cell line.

TARGATT? Knock-in iPSC Quick Knockin Kit

AST-1101 Applied StemCell 1 Kit Ask for price
Description: 12 month

Rrad ORF Vector (Rat) (pORF)

ORF075643 ABM 1.0 ug DNA 607.2 EUR

Rrad ORF Vector (Mouse) (pORF)

ORF056448 ABM 1.0 ug DNA 607.2 EUR

Anti-RRAD (aa36-48) antibody

STJ72757 St John's Laboratory 100 µg 430.8 EUR

Anti-HeLa HCP, Affinity Purified

HL59/73-AF Cygnus Technologies 1 mg 2295.6 EUR
Description: Anti-HeLa HCP, Affinity Purified by Cygnus Technologies is available in Europe via Gentaur.

HeLa HCP Std. A-H

F813 Cygnus Technologies 1 ml 585.6 EUR
Description: HeLa HCP Std. A-H by Cygnus Technologies is available in Europe via Gentaur.

Hela-GFP stable cells (Blasticidin)

SC034-Bsd GenTarget 2 x 106 cell/ml x 1ml 930 EUR
Description: GFP expression stable cell line in Hela cells with Blasticidin marker.

Hela-GFP stable cells (Puromycin)

SC034-Puro GenTarget 2 x 106 cell/ml x 1ml 930 EUR
Description: GFP expression stable cell line in Hela cells with Puromycin marker.

Hela-TetR (Puro) stable cells

SC035-Puro GenTarget 2 x 106 cell/ml x 1ml 1452 EUR
Description: tetracycline repressor expression Hela stable cell line with Puromycin marker

HeLa Nuclear Extract (DTT-free)

7947-01 Biovision each 222 EUR

HeLa Nuclear Extract (DTT-free)

7947-1 Biovision each 379.2 EUR

RRAD Protein Vector (Human) (pPB-C-His)

PV127326 ABM 500 ng 662.4 EUR

RRAD Protein Vector (Human) (pPB-N-His)

PV127327 ABM 500 ng 662.4 EUR

RRAD Protein Vector (Human) (pPM-C-HA)

PV127328 ABM 500 ng 662.4 EUR

RRAD Protein Vector (Human) (pPM-C-His)

PV127329 ABM 500 ng 662.4 EUR

Human HeLa-S3 (Cervix Epithelioid Carcinoma) lysate

HCL-1201 Alpha Diagnostics 100ug 285.6 EUR

RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)

K2069905 ABM 3 x 1.0 ug 451.2 EUR

Swing-out rotor 6-place

CEN0179 Scientific Laboratory Supplies EACH 607.62 EUR

Swing-out rotor 8-place

CEN0180 Scientific Laboratory Supplies EACH 701.1 EUR

Swing-out rotor 12-place

CEN0181 Scientific Laboratory Supplies EACH 531.24 EUR

Rotor Swing out 6x5ml RB

CEN2634 Scientific Laboratory Supplies EACH 429.78 EUR

Rotor Swing out 2x3MTP ID

CEN2664 Scientific Laboratory Supplies EACH 1299.6 EUR

Autoclave Print-Out PAPER CR70

SXP374 Scientific Laboratory Supplies EACH 40.7 EUR

Platinum-E Retroviral Packaging Cell Line, Ecotropic

RV-101 Cell Biolabs 1 vial 1104 EUR
Description: Conventional cells used for retrovirus packaging, such as those based on NIH3T3 cells, have limited stability and produce relatively low yields of retrovirus, mainly due to the poor expression of retroviral structure proteins (gag, pol and env) in the cells. The Platinum Retroviral Packaging Cell Lines are based on the 293T cell line. They exhibit longer stability and produce higher yields of retroviral structure proteins. Plat-E cells contain gag, pol and env genes, allowing retroviral packaging with a single plasmid transfection.

Platinum-A Retroviral Packaging Cell Line, Amphotropic

RV-102 Cell Biolabs 1 vial 1104 EUR
Description: Conventional cells used for retrovirus packaging, such as those based on NIH3T3 cells, have limited stability and produce relatively low yields of retrovirus, mainly due to the poor expression of retroviral structure proteins (gag, pol and env) in the cells. The Platinum Retroviral Packaging Cell Lines are based on the 293T cell line. They exhibit longer stability and produce higher yields of retroviral structure proteins. Plat-A cells contain gag, pol and env genes, allowing retroviral packaging with a single plasmid transfection.

Platinum-GP Retroviral Packaging Cell Line, Pantropic

RV-103 Cell Biolabs 1 vial 1104 EUR
Description: Conventional cells used for retrovirus packaging, such as those based on NIH3T3 cells, have limited stability and produce relatively low yields of retrovirus, mainly due to the poor expression of retroviral structure proteins (gag, pol and env) in the cells. The Platinum Retroviral Packaging Cell Lines are based on the 293T cell line. They exhibit longer stability and produce higher yields of retroviral structure proteins. Plat-GP cells contain the gag and pol genes required for retroviral packaging; an expression vector is co-transfected with a VSVG envelope vector.

Total Protein - Murine Embryonic Stem Cell Line D3

CBA-305 Cell Biolabs 500 ?g 414 EUR
Description:
  • Isolated from mouse ES-D3 cell line
  • Presented as 500 µg at 1 mg/mL in NP-40 Solubilization Buffer

RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1)

K2069906 ABM 1.0 ug DNA 200.4 EUR

RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2)

K2069907 ABM 1.0 ug DNA 200.4 EUR

RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3)

K2069908 ABM 1.0 ug DNA 200.4 EUR

Human GTP-binding protein RAD (RRAD) ELISA Kit

abx385354-96tests Abbexa 96 tests 1093.2 EUR

Human GTP- binding protein RAD, RRAD ELISA KIT

ELI-35549h Lifescience Market 96 Tests 988.8 EUR

GTP-Binding Protein RAD (RRAD) Antibody

20-abx008742 Abbexa
  • 360.00 EUR
  • 526.80 EUR
  • 226.80 EUR
  • 100 ul
  • 200 ul
  • 30 ul

GTP-binding protein RAD (RRAD) Antibody

abx332370-100ul Abbexa 100 ul 510 EUR

GTP-binding protein RAD (RRAD) Antibody

20-abx241706 Abbexa
  • 493.20 EUR
  • 360.00 EUR
  • 100 ul
  • 50 ul

GTP-binding protein RAD (RRAD) Antibody

20-abx324872 Abbexa
  • 376.80 EUR
  • 292.80 EUR
  • 100 ug
  • 50 ug

GTP-Binding Protein RAD (RRAD) Antibody

abx432011-200ul Abbexa 200 ul 460.8 EUR

GTP-binding protein RAD (RRAD) Antibody

20-abx214509 Abbexa
  • 493.20 EUR
  • 360.00 EUR
  • 100 ul
  • 50 ul

HeLa Nuclear Extract (Epithelioid carcinoma cells)

NHELA-100 Alpha Diagnostics 100 ug 196.8 EUR

HeLa Nuclear Extract (Epithelioid carcinoma cells)

NHELA-50 Alpha Diagnostics 50 ug 153.6 EUR

Luciferase (firefly), Hela stable cells (Blasticidin)

SC032-Bsd GenTarget 2 x 106 cell/ml x 1ml 1452 EUR
Description: Luciferase (firefry) expression stable cell line in Hela cells with Blasticidin marker.

Luciferase (firefly), Hela stable cells (Puromycin)

SC032-Puro GenTarget 2 x 106 cell/ml x 1ml 1452 EUR
Description: Luciferase (firefry) expression stable cell line in Hela cells with Puromycin marker.

Hela-rtTA (GFP-Bsd) stable cells

SC038-GB GenTarget 2 x 106 cell/ml x 1ml 1974 EUR
Description: rtTA (reverse tetracycline Transcriptional Activator) expression Hela stable cell line with GFP-Blasticidin fusion dual marker

Hela-rtTA (GFP-Puro) stable cells

SC038-GP GenTarget 2 x 106 cell/ml x 1ml 1974 EUR
Description: rtTA (reverse tetracycline Transcriptional Activator) expression Hela stable cell line with GFP-Puromycin fusion dual marker
×
However, once we additional carried out a sensitivity analysis, FPRP, and BFDP take a look at, less-credible optimistic outcomes had been recognized (all FPRP > 0.2 and BFDP > 0.8) in any important affiliation.In abstract, this research strongly signifies that every one important associations had been much less credible optimistic outcomes, fairly than from true associations.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recent Posts

  • Compare Appoptosis lab reagents for research
  • Compare ELISA lab reagents for research
  • Treating Diabetes Utilizing a Low Carbohydrate Ketogenic Diet and Intermittent Fasting Without Significant Weight Loss: A Case Report
  • Discovering common pathogenetic processes between COVID-19 and diabetes mellitus by differential gene expression pattern analysis
  • The Effect of Integrated Intervention Based on Protection Motivation Theory and Implementation Intention to Promote Physical Activity and Physiological Indicators of Patients with Type 2 Diabetes

Distributors

Europe Gentaur group

Archives

  • December 2022
  • September 2021
  • August 2021
  • July 2021
  • October 2020
  • May 2020
  • February 2020

Categories

  • blood
  • Blot
  • cDNA
  • ChiP
  • coli recombinant
  • colorimetric
  • Control
  • dna
  • Effects of Laser Acupuncture and Dietary Intervention on Key Obesity Parameters.
  • elektroporation
  • elisa
  • Prevalence, clinical characteristics, risk factors, and indicators for lean Chinese adults with nonalcoholic fatty liver disease.
  • Prospect of Sodium-Glucose Co-transporter 2 Inhibitors Combined With Insulin for the Treatment of Type 2 Diabetes.
  • protein
  • Rabbit
  • Rat
  • rna
  • Salmonella
  • Sheep
  • step
  • sterile
  • The Cost-Effectiveness of Lifestyle Interventions for Preventing Diabetes in a Health Resource-Limited Setting.
  • The Need for Diabetes Care Customization in the ICU at the Time of SARS-CoV-2 Outbreak.
  • Torpedo
  • Trout
  • Yeast
  • blood
  • Blot
  • cDNA
  • ChiP
  • coli recombinant
  • colorimetric
  • Control
  • dna
  • Effects of Laser Acupuncture and Dietary Intervention on Key Obesity Parameters.
  • elektroporation
  • elisa
  • Prevalence, clinical characteristics, risk factors, and indicators for lean Chinese adults with nonalcoholic fatty liver disease.
  • Prospect of Sodium-Glucose Co-transporter 2 Inhibitors Combined With Insulin for the Treatment of Type 2 Diabetes.
  • protein
  • Rabbit
  • Rat
  • rna
  • Salmonella
  • Sheep
  • step
  • sterile
  • The Cost-Effectiveness of Lifestyle Interventions for Preventing Diabetes in a Health Resource-Limited Setting.
  • The Need for Diabetes Care Customization in the ICU at the Time of SARS-CoV-2 Outbreak.
  • Torpedo
  • Trout
  • Yeast
  • Compare Appoptosis lab reagents for research
  • Compare ELISA lab reagents for research
  • Treating Diabetes Utilizing a Low Carbohydrate Ketogenic Diet and Intermittent Fasting Without Significant Weight Loss: A Case Report
  • Discovering common pathogenetic processes between COVID-19 and diabetes mellitus by differential gene expression pattern analysis
  • The Effect of Integrated Intervention Based on Protection Motivation Theory and Implementation Intention to Promote Physical Activity and Physiological Indicators of Patients with Type 2 Diabetes
© 2023 Prosidion Ltd. | Powered by Superbs Personal Blog theme